Unconventional Presentation of Multiple Myeloma: A Case Study
Abstract
Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of plasma cells within the bone marrow, often presenting with classic symptoms such as bone pain, anemia, hypercalcemia, renal dysfunction, and recurrent infections. As the second most common blood cancer, it represents about 1% of all cancer cases, contributes to 2% of cancer-related deaths, and comprises 12–15% of oncological and hematological disorders. . Renal failure is a significant concern for multiple myeloma patients, often stemming from tubulointerstitial pathology caused by high levels of circulating monoclonal immunoglobulin free light chains. These proteins can induce kidney problems including proximal tubule cell toxicity, tubulointerstitial nephritis, and myeloma kidney (cast nephropathy). Less frequently, elevated free light chains may lead to conditions like immunoglobulin light chain amyloidosis and light chain deposition disease, which typically exhibit a slow progression of renal failure rather than acute injury. early diagnosis and appropriate treatment is crucial. This case presents an unusual presentation of multiple myeloma, resulting in a delay in both diagnosis and treatment initiation. It is crucial for clinicians to persist in reporting unusual presentations of multiple myeloma and to view it as a potential diagnosis in patients exhibiting serious and uncommon symptoms.
How to Cite This Article
Abbas A, Rasool U. Unconventional Presentation of Multiple Myeloma: A Case Study. J Pak Soc Intern Med. 2026;7(1):81–83. doi:10.70302/jpsim.v7i1.2617
Conflict of Interest
All authors declare no competing interests.
Funding
No specific funding was received for this research.
Funder information follows the Crossref Funder Registry standard.
References
- Mousavi SE, Ilaghi M, Aslani A, Yekta Z, Nejadghaderi SA. A population-based study on incidence trends of myeloma in the United States over 2000-2020. Sci Rep. 2023;13(1):20705.
- Liu J, Liu W, Mi L, Zeng X, Cai C, Ma J, et al. Incidence and mortality of multiple myeloma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016. J Hematol Oncol. 2019;12(1):136.
- Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, et al. Epidemiology, staging, and management of multiple myeloma. Medical Sciences. 2021;9(1):3.
- Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21-33.
- Leung N, Rajkumar SV. Multiple myeloma with acute light chain cast nephropathy. Blood Cancer J. 2023;13(1):46.
- Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548-67.
- Royal V, Leung N, Troyanov S, Nasr SH, Écotière L, LeBlanc R, et al. Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study. Blood. 2020;135(21):1833-46.
- Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood. 2015;125(20):3069-75.
- Blum A, Bazou D, O'Gorman P. Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions. Blood Lymphat Cancer. 2018;8(1):21-31.
- Rajkumar S, Abdallah N, Lakshman A, Kumar S, Cook J, Binder M, et al. Mode of Progression in Smoldering Multiple Myeloma: A study of 406 patients. Res Sq. 2023; doi: 10.21203/rs.3.rs-3378634/v1. doi:10.21203/rs.3.rs-3378634/v1
Reference list indexed for Google Scholar and ResearchGate. DOI links resolve via doi.org.